Filing Details
- Accession Number:
- 0001209191-20-030466
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2020-05-19 16:22:25
- Reporting Period:
- 2020-05-15
- Accepted Time:
- 2020-05-19 16:22:25
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 875320 | Vertex Pharmaceuticals Inc / Ma | VRTX | Pharmaceutical Preparations (2834) | 043039129 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1557290 | A Stuart Arbuckle | C/O Vertex Pharmaceuticals Incorporated 50 Northern Avenue Boston MA 02210 | Evp, Chief Commercial Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Disposition | 2020-05-15 | 10 | $276.35 | 35,282 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2020-05-15 | 17 | $279.93 | 35,265 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2020-05-15 | 12 | $280.71 | 35,253 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2020-05-15 | 10 | $283.58 | 35,243 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2020-05-15 | 10 | $285.00 | 35,233 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2020-05-15 | 21 | $286.41 | 35,212 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2020-05-15 | 24 | $287.62 | 35,188 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2020-05-15 | 9 | $288.35 | 35,179 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Non-Derivative Holdings
| Sec. Name | Remaning Holdings | Nature of Ownership | Explanation |
|---|---|---|---|
| Common Stock | 140 | Indirect | 401(k) |
Footnotes
- Transaction made pursuant to Mr. Arbuckle's company approved trading plan under Rule 10b5-1.
- Open market sales reported on this line occurred at a weighted average price of $279.93 (range $279.38 to $280.31).
- Mr. Arbuckle undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- Open market sales reported on this line occurred at a weighted average price of $280.71 (range $280.41 to $280.86).
- Open market sales reported on this line occurred at a weighted average price of $286.41 (range $286.16 to $287.04).
- Open market sales reported on this line occurred at a weighted average price of $287.62 (range $287.21 to $287.99).
- Open market sales reported on this line occurred at a weighted average price of $288.35 (range $288.23 to $288.43).
Billionaire Hedge Funds
